gap junction protein alpha 6, pseudogeneGenealiases: []
Q-omics provides the consensus-scored GJA6P profile across patient tissues and cancer cell-line models. GJA6P expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, GJA6P is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, GJA6P RNA expression shows 8,154 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight OV, STAD, and GBM as cancer lineages where GJA6P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GJA6P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GJA6P survival associations across molecular data types. GJA6P RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GJA6P RNA expression–survival associations across cancer types. High GJA6P expression shows unfavorable associations in LUSC, UVM, LIHC, KIRC and LGG, but favorable associations in OV. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify OV as the clearest survival context for GJA6P RNA expression.
This table summarizes GJA6P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for GJA6P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GJA6P shows higher tumor expression in STAD. The STAD box plot shows higher GJA6P RNA expression in tumor versus normal tissue (log2 FC = +0.041, t-test p = .009).
This table shows molecular features associated with GJA6P in patient tissues and cancer cell lines. In patient samples, GJA6P shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
